Introduction {#sec1}
============

Colorectal cancer (CRC) is one of the major causes of cancer-associated morbidity and mortality in developing and well-developed countries. It is the second most prevalent cancer, and one that affects men and women almost equally. Approximately 600,000 deaths from CRC are estimated worldwide each year, representing 8% of all cancer deaths, which makes it the fourth leading cause of death among all malignancies \[[@cit0001]\].

Maintaining the integrity of genomic DNA is necessary for correct cell function. Genome disorders can contribute to the development of several malignancies, including CRC. The CRC can be initiated by DNA damage induced by chemical agents, smoking, alcohol consumption, and fat metabolism. A number of single nucleotide polymorphisms (SNP) have been identified in a group of more than 130 known DNA repair genes \[[@cit0002]\]. The presence of polymorphisms in repair genes may influence their efficiency to eliminate DNA damage and thereby increase the chance of cancer. The human mismatch repair (MMR) system repairs DNA misinformation or damage. Microsatellite regions are especially susceptible to mutations and polymorphisms due to slippage of DNA polymerase during DNA replication, and failure to excise these errors may lead to frameshift mutations in many genes.

MLH1, MSH2, MSH6, and PMS2 are major MMR genes implicated in genetic stability \[[@cit0003]\], with germline mutations in these MMR genes being responsible for hereditary non-polyposis colorectal cancer (HNPCC). The presence of single nucleotide polymorphisms (SNPs) in the MMR genes can also predispose the patient to non-familial CRC by contributing common genetic variants of CRC susceptibility in a given population \[[@cit0004]\]. However, although approximately 70% of sporadic cancer is caused by external factors, some studies suggest the possibility of a genetic predisposition associated with alterations in DNA repair genes, including the MMR genes. Furthermore, other studies suggest that the presence of MMR gene polymorphisms may have an influence on the late outcomes of treating CRC patients \[[@cit0005]\].

The aim of this study was to determine the effect of SNP --93G\>A of the *MLH1* gene and Gly322Asp of *MSH2* on the risk of colon cancer in the studied population in comparison with healthy subjects, and to identify differences in allele distribution between different subgroups of colon cancer patients according to age, sex, tumor location, some pathological findings, staging and severity of the disease.

Material and methods {#sec2}
====================

The recruited subjects comprised a case group of patients with histologically confirmed colon cancer and a control group of healthy, unrelated volunteers. DNA was isolated from peripheral blood lymphocytes obtained from blood samples taken from the subjects.

The study was conducted in accordance with the approval of the Local Ethics Committee of the Medical University of Lodz (no. RNN/693/14/KB). The subjects were fully informed of the nature of the study and each gave their written consent before taking part. The study design conforms with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

The study group consisted of 144 unrelated patients (71 men and 73 women; mean age: 61.7 ±11) with pathologically confirmed colon cancer. None had any family history of any malignancies. The control group comprised 151 unrelated patients without any confirmed malignancies (74 men and 77 women; mean age: 63 ±11). All patients and controls were cross-matched according to age and gender. The patients in the study group were operated on between July and December 2014 in the university tertiary colorectal center for primary or recurrent disease. All surgical procedures were performed by a specialized surgical team according to colorectal cancer surgery guidelines.

We analyzed the influence of SNP in 93G\>A *MLH1* (rs1800734) and Gly322Asp *MSH2* (rs4987188) and the risk of CC in a population in central Poland. Subgroups of colon cancer patients were formed to investigate the relationship between the distribution of MMR gene alleles according to selected groups of clinical factors.

Polymorphism analysis {#sec2.1}
---------------------

### hMLH1-93 G\>A genotyping by PCR-RFLP {#s2a1}

DNA was extracted from peripheral blood lymphocytes using DNA Blood Mini Kits (A&A Biotechnology, Gdynia, Poland). Genotypes were determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach. The PCR was carried out in a volume of 10 μl. The reaction mixture consisted of 100 ng of genomic DNA, 0.5 μmol of each primer and 3 U of Taq polymerase. The PCR cycling conditions consisted of an initial denaturation step of 95°C for 10 min, followed by 40 cycles of 95°C for 30 s, 56°C for 45 s and 72°C for 45 s, followed by a final extension stage of 72°C for 10 min. The 10 μl of specifically positive PCR products was digested overnight with 1 μl of *PvuII* (New England Bio Labs, Beverly, MA) at 37°C and digested DNA fragments were resolved on 3% agarose gel. The homozygous AA genotype gave undigested fragments of 387 bp while the homozygous GG genotype yielded two digested fragments of sizes 207 bp and 180 bp. The AG heterozygous condition revealed three bands sized 387 bp, 207 bp and 180 bp ([Figure 1](#f0001){ref-type="fig"}). The randomly selected PCR-amplified DNA samples for each genotype were cross-checked by DNA sequencing and the results were found to be 100% concordant.

![Analysis of genotype polymorphism --93G\>A gene *hMLH1* after hydrolysis with restriction enzyme PvuII. Track 1 marker tracks 6, homozygous AA (one band at 387 bp), lane 2, 7, heterozygous GG (two bands of size 180 bp, 207 bp) lane 3, 4, 5, 8 is heterozygous AG (three bands of the size 180 bp, 207 bp and 387 bp)](AMS-13-29777-g001){#f0001}

### HMSH2 Gly322Asp {#s2a2}

DNA was extracted from peripheral blood lymphocytes using DNA Blood Mini Kits (A&A Biotechnology, Gdynia, Poland). Genotypes were determined by PCR-RFLP. The procedure was carried out in a volume of 10 μl. The reaction mixture consisted of 100 ng of genomic DNA, 0.5 μmol of each primer and 3 U of Taq polymerase. The PCR cycling conditions consisted of an initial denaturation step of 95°C for 5 min, followed by 30 cycles of 95°C for 30 s, at the annealing temperature of 60°C, and at 72°C for 30 s and then a final extension of 72°C for 5 min. The 10 μl of specifically positive 252 bp PCR products was digested overnight with 1 μl of *HinfI* (New England Bio Labs, Beverly, MA) at 37°C, and the digested DNA fragments were resolved on 3% agarose gel. The Asp allele was digested into 70 and 182 bp fragments, whereas the Gly variant remained intact ([Figures 2](#f0002){ref-type="fig"}, [3](#f0003){ref-type="fig"}, [Table I](#t0001){ref-type="table"}).

###### 

Primers, length of PCR products and restriction enzymes

  -------------------------------------------------------------------------------------------
  Polymorphism      Primers     Product length \[bp\]         Restriction enzyme   
  ----------------- ----------- ----------------------------- -------------------- ----------
  MLH1 --93G\>A\    Sense\      5'-CCGAGCTCCTAAAAACGAAC-3'\   387                  *PvuII*\
  (rs1800734)       Antisense   5'-CTGGCCGCTGGATAACTTC-3'                          (37°C)

  MSH2 Gly322Asp\   Sense\      5'-GTTTTCACTAATGAGCTTGC-3'\   252                  *HinfI*\
  (rs4987188)       Antisense   5'-AGTGGTATAATCATGTGGGT-3'                         (37°C)
  -------------------------------------------------------------------------------------------

![Analysis of genotype polymorphism Gly322Asp gene *hMSH2* after hydrolysis with restriction enzyme *HinfI*. Track 1 marker tracks 1, 2, 3, 4, 5, 6, 7 homozygous GG](AMS-13-29777-g002){#f0002}

![Analysis of genotype polymorphism Gly322Asp gene *hMSH2* after hydrolysis with restriction enzyme *HinfI*. Track 1 marker, lane 5, heterozygous AG 2, 3, 4, 6, 7, 8, is heterozygous AA](AMS-13-29777-g003){#f0003}

Statistical analysis {#sec2.2}
--------------------

The frequency of the analyzed polymorphisms was evaluated using the Hardy-Weinberg equilibrium test among CRC patients and case controls. The odds ratios (OR) and 95% confidence intervals (95% CI) were adjusted for age and gender. Means were compared by *t*-test or analysis of variance. Logistic regression analysis was performed to estimate the statistical association between SNP genetic variants and the risk of colon cancer. The χ^2^ test with Yates' correction was used to analyze the distribution of the alleles according to age, gender, tumor location, grading, nodal involvement, distant metastases and recurrence. *P*-values were calculated as two-sided. Probabilities were considered significant at *p*-values less than 0.05.

Results {#sec3}
=======

For *MLH1* --93G\>A, the G/G genotype was found in 74 patients with colon cancer (51.4%), A/G in 45 (31.2%) patients and A/A in 25 (17.4%) patients, while for the control subjects, G/G was found in 53 subjects (35.1%), A/G in 61 (40.4%) and A/A in 37 (24.5%). The G/G genotype was found to be associated with an increased risk of sporadic colon cancer in patients compared with control cases (OR = 2.07; 95% CI: 1.11--3.83; *p* \< 0.02); however, no such influence was found for A/G heterozygotes (OR = 1.09; 95% CI: 0.58--2.05; *p* = 0.7).

For *MSH2* Gly322Asp, neither homozygous A/A (OR = 1.44; 95% CI: 0.32--6.56; *p* = 0.7) nor A/G (OR = 2.70; 95% CI: 0.52--14.17; *p* = 0.2) was found to have any influence on the risk of sporadic cancer in the study population. A more detailed distribution of genotypes and alleles for the case group and control group is shown in [Table II](#t0002){ref-type="table"}.

###### 

MSH2 Gly322Asp and MLH1 -93G\>A polymorphisms and the risk of colon cancer in studied population

  Genotype/allele   Case patients, *n* (%)   Control subjects, *n* (%)   OR (95% CI)          *P*-value
  ----------------- ------------------------ --------------------------- -------------------- -----------
  Total             144 (100)                151 (100)                   --                   --
  MSH2 Gly322Asp:                                                                             
   G/G              135 (93.8)               146 (96.7)                  1.00 (referent)      
   A/G              5 (3.5)                  2 (1.3)                     2.70 (0.52--14.17)   0.2
   A/A              4 (2.7)                  3 (2.0)                     1.44 (0.32--6.56)    0.7
   G                275 (95)                 294 (97.4)                  1.00 (referent)      
   A                13 (5)                   8 (2.6)                     1.74 (0.71--4.26)    0.2
  MLH1 -- 93G\>A:                                                                             
   A/A              25 (17.4)                37 (24.5)                   1.00 (referent)      
   A/G              45 (31.2)                61 (40.4)                   1.09 (0.58--2.05)    0.7
   G/G              74 (51.4)                53 (35.1)                   2.07 (1.11--3.83)    **0.02**
   A                95 (33.0)                135 (44.7)                  1.00 (referent)      
   G                193 (67.0)               167 (55.3)                  1.66 (1.19--2.32)    **0.002**

In the studies on colon cancer patients, the frequency of the *MLH1*-93G\>A polymorphisms was higher in women than in men: 28 (38.4%) vs. 17 (23.9%) for A/G and 16 (21.9%) vs. 9 (12.7%) for A/A, and the distribution differed significantly (*p* = 0.034).

The relationship between tumor location and the distribution of the *MLH1* --93G\>A polymorphisms was also examined. In left-side colon tumors, the frequency of the A/G genotype was significantly higher than in right-sided tumors, 38 (39.6%) vs. 7 (14.6%), but the percentage of the A/A genotype was only slightly lower in left colon cancer, 16 (16.6%) vs. 9 (18.7%) (*p* = 0.014).

In recurrent disease, the frequency of the A/G genotype was significantly lower than in primary tumor, 1 (5.6%) vs. 44 (34.9%), but A/A homozygotes were more frequent in recurrent tumors; 7 (38.9%) vs. 18 (14.3%), *p* = 0.022.

For the *MLH1* --93G\>A polymorphism, no other significant differences were observed with regard to other pathological or clinical factors. All details are given in [Table III](#t0003){ref-type="table"}.

###### 

MLH1 --93G\>A polymorphisms and analyzed clinical features of patients with non-familial colon cancer

  Clinical feature      *N*   MLH1 genotype, *n* (%)   Yates' χ^2^   *P*-value                   
  --------------------- ----- ------------------------ ------------- ----------- ------- ------- --
  Total                 144   74 (51.4)                45 (31.2)     25 (17.4)   N/A     N/A     
  Gender:                                                                                        
   Male                 71    45 (63.4)                17 (23.9)     9 (12.7)    7.52    0.034   
   Female               73    29 (39.7)                28 (38.4)     16 (21.9)                   
  Age:                                                                                           
   \< 50                21    13 (61.9)                5 (23.8)      3 (14.3)    0.523   0.769   
   \> 50                123   61 (49.6)                40 (32.5)     22 (17.9)                   
  Tumor location:                                                                                
   Right colon          48    32 (66.7)                7 (14.6)      9 (18.7)    8.47    0.014   
   Left colon           96    42 (43.8)                38 (39.6)     16 (16.6)                   
  Tumor grading:                                                                                 
   Well                 15    9 (60.0)                 4 (26.7)      2 (13.3)                    
   Moderate             114   58 (50.9)                36 (31.6)     20 (17.5)   0.115   0.998   
   Poor                 15    7 (46.7)                 5 (33.3)      3 (20.0)                    
  Nodal involvement:                                                                             
   Yes                  98    49 (50.0)                29 (29.6)     20 (20.4)   1.31    0.519   
   No                   46    25 (54.3)                16 (34.8)     5 (10.9)                    
  Distant metastases:                                                                            
   Yes                  25    18 (72.0)                5 (20.0)      2 (8.0)     3.81    0.149   
   No                   119   56 (47.1)                40 (33.6)     23 (19.3)                   
  Recurrent disease:                                                                             
   Yes                  18    10 (55.5)                1 (5.6)       7 (38.9)    7.63    0.022   
   No                   126   64 (50.8)                44 (34.9)     18 (14.3)                   

Due to the small number of examples of A/G and A/A of polymorphism *MSH2* Gly322Asp, the numbers were summarized. Higher frequencies of the A/G plus A/A genotypes of *MSH2* Gly322Asp were found in recurrent than in primary disease: 4 (22.2%) vs. 5 (4.0%) (*p* = 0.001). No other clinical or pathological factors influenced the SNP genotype distribution ([Table IV](#t0004){ref-type="table"}).

###### 

MSH2 Gly322Asp polymorphisms and analyzed clinical features of patients with non-familial colon cancer

  Clinical feature      *N*     MSH2 genotype, *n* (%)   Yates' χ^2^   *P*-value   
  --------------------- ------- ------------------------ ------------- ----------- -------
                                GG                       AA + AG                   
  Total                 144     135 (93.8)               9 (6.2)       N/A         N/A
  Gender:                                                              0.42        0.518
   Male                 71      68 (95.8)                3 (4.2)                   
   Female               73      67 (91.8)                6 (8.2)                   
  Age:                  0.76    0.856                                              
   \< 50                21      20 (95.2)                1 (4.8)                   
   \> 50                123     115 (93.5)               8 (6.5)                   
  Tumor location:       0.13    0.715                                              
   Right colon          48      44 (91.7)                4 (8.3)                   
   Left colon           96      91 (94.8)                5 (5.2)                   
  Tumor grading:        0.64    0.727                                              
   Well                 15      14 (93.3)                1 (6.7)                   
   Moderate             114     108 (94.7)               6 (5.3)                   
   Poor                 15      13 (86.7)                2 (13.3)                  
  Nodal involvement:                                                   0.08        0.781
   Yes                  98      92 (93.9)                6 (6.1)                   
   No                   46      43 (93.5)                3 (6.5)                   
  Distant metastases:   0.73    0.394                                              
   Yes                  25      22 (88.0)                3 (12.0)                  
   No                   119     113 (94.6)               6 (5.4)                   
  Recurrent disease:    12.34   0.001                                              
   Yes                  18      14 (77.8)                4 (22.2)                  
   No                   126     121 (96.0)               5 (4.0)                   

Discussion {#sec4}
==========

This case-control study analyzes two SNPs of the *MLH1* and *MSH2* mismatch repair genes and their influence on malignant transformation in the human colon. It also investigates the associations between genetic characteristics, the clinical and pathological factors of the tumor and the genetic models of the studied SNPs.

Some rare constitutional mutations and methylations of MMR genes (including MLH1 and MSH2) are known to be primary causes of autosomal dominant disorders, such as hereditary non-polyposis colorectal cancer (HNPCC). However, the study focused on the properties of SNPs in patients with sporadic colon cancer, as the presence of SNPs in the MMR genes is associated with a higher risk of colon cancer, with low to moderate penetration in some populations with only sporadic tumors \[[@cit0006], [@cit0007]\].

As two transcription binding sites, NF-IL6 and GT-IIB, exist in this promoter region of the *MLH1* gene, the --93G\>A polymorphism is functional and may alter *MLH1* transcription and expression, thereby changing DNA repair abilities. The studied SNP of the *MLH1* gene is located within its promoter region, which accounts for the maximal activity of *MLH1* transcription \[[@cit0008]\].

The --93G\>A polymorphism was found to be associated with a higher risk of colon cancer in our studied population. Many previous studies have found SNPs to be associated with increased risk of CRC \[[@cit0009]--[@cit0011]\]; however, results across other studies have been inconclusive. A meta-analysis by Whiffin *et al.* found that the --93G\>A polymorphism (heterozygous genotype) increased the risk of CRC in a population consisting of 14121 CRC cases and 10 890 controls \[[@cit0012]\]. Another meta-analysis by Pan *et al.* did not identify any such association, but the group included in the study seemed to have incorrect information: the control group included some individuals with no proven absence of CRC history, which could have influenced the results \[[@cit0013]\]. A meta-analysis of six case-controlled studies published in 2012 by Wang *et al.* found that the presence of the --93G\>A*MLH1* polymorphism in two genetic patterns, A/A vs. G/G and AA/AG vs. G/G, was significantly associated with a higher risk of CRC. The population included in the analysis was large and consisted of 17 791 CRC cases and 13 782 controls \[[@cit0008]\].

As in the present study, Martinez-Urueña *et al.* also found a statistically significant relationship between a homozygous --93G\>A polymorphism in the *MLH1* gene and the risk of sporadic CRC. In addition, the relationship was absent in patients with a family history of CRC \[[@cit0014]\].

The present study also tried to determine whether the presence of the Gly322Asp polymorphism of *MSH2* was associated with a higher risk of CRC. Although no such association was reported in a previous study, the analysis was insufficient for such conclusions and the study group included HNPCC patients \[[@cit0015]\]. Smolarz *et al.* recently reported that one of the genetic variants of Gly233Asp decreased the risk of triple-negative breast cancer in a Polish population \[[@cit0016]\] -- hence the choice of the same SNP for the present study, which is based on an analysis of colon cancer patients without a family history of cancer taken from a similar population. No significant association was found between any of the genetic models of Gly233Asp *MSH2* and the risk of colon cancer in our group. Nevertheless, although no significant correlation was found, further studies are merited due to the fact that few such studies have been published, especially on sporadic colorectal cancer patients.

The present study attempts to analyze the distribution of polymorphism genotypes according to various clinical factors. In the 1990s, Bufill proposed division of the colon into a right and left-sided organ, believing that anatomical factors can influence the clinical differences observed in CRC tumors, as well as the known genetic, biological and pathological factors \[[@cit0017]\]. Many authors have since found that left- and right-sided colon cancer may be considered two different disease entities with differing disease spread, length of outcome and prognosis \[[@cit0018], [@cit0019]\]. A fuller understanding of the basis of these differences would be valuable in that it might influence the treatment or screening of patients with colon cancer. In accordance with other studies, our findings indicate that right and left-sided colon cancers differ with regard to the distribution of the genotype of the *MLH1* gene SNP \[[@cit0005], [@cit0010], [@cit0020]\]; these relationships should also be taken into account in further studies. However, no such relationships were found between the distribution of the *MSH2* Gly322Asp SNP and tumor location. Unfortunately, due to the paucity of analyses available in the literature, it is impossible to compare our findings with others.

We observed a relationship between the SNP genotype for *MLH1* and sex, as well as with the presence of recurrent disease. The A allele was more common in the studied women. As, generally speaking, men are known to be slightly more likely to develop colorectal cancer than women, it is possible that the presence of the A allele, among other factors, can have a protective influence and reduce the risk of CRC in this group of individuals. What makes our findings particularly is the fact that the subjects are not divided according to gender in molecular research. The findings need to be evaluated on the basis of a larger study group.

We also found that patients with recurrent disease were significantly more likely to possess a copy of the A allele for the *MLH1* gene SNP than patients with only a primary tumor. These results also should be re-evaluated using larger study groups, together with other factors as part of a multivariate analysis.

In the *MSH2* Gly322Asp polymorphism, the frequency of the A allele was found to be higher in recurrent than in primary disease. However, due to the small number of cases in the group, further studies are necessary to gain a fuller picture of the situation.

One limitation of the study is its small sample size. However, the homogeneity of sporadic colon cancer cases and controls can be an advantage for genetic evaluation, especially in the analysis of polymorphisms. A greater insight is needed into the relationships between the SNPs of studied MMR genes and clinical factors. Although any further analyses should be based on larger sample sizes, the best study format for genetic assessments, precise clinical databases, are sometimes very difficult to obtain for population-based studies with large numbers of cases.

In conclusion, the *MLH1* --93G\>A polymorphism plays an important role in evaluating the risk of sporadic colon cancer not only in HNPCC patients. It may also be used as an indicator in some groups of patients with left-sided and recurrent tumors.

The MSH2 Gly322Asp polymorphism may also be used as a marker in patients with high risk of recurrent disease. However, this needs to be confirmed in further studies and by multivariate analysis.
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